Business UpdateJul 21, 2026, 08:57 AM
Silo Pharma AI platform to launch in 60-90 days; PTSD drug advances
AI Summary
Silo Pharma provided an update on the commercialization progress of its AI subsidiary, QwikAgents, and the advancement of its lead PTSD therapeutic program, SPC-15. The company expects to commercially launch its enhanced AI agent platform within the next 60-90 days, aiming to generate initial revenue. Concurrently, Silo is strengthening the intellectual property for SPC-15 and completing final regulatory activities for an FDA Type C meeting request, followed by an Investigational New Drug (IND) submission. The company states it is well-capitalized to pursue these opportunities after a recent private placement.
Key Highlights
- Silo Pharma's QwikAgents AI platform expects commercial launch within 60-90 days.
- The AI platform is anticipated to begin generating initial revenue post-launch.
- SPC-15 drug-device robustness study for PTSD therapeutic expected to complete within 60 days.
- Company is strengthening intellectual property for SPC-15 through additional patent filings.
- SPC-15 is advancing towards an FDA Type C meeting request and Investigational New Drug (IND) submission.
- Silo Pharma is well-capitalized following a recently announced private placement.
Price Impact
More from SILO